Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells

Non-Hodgkin lymphoma (NHL) is one of the most common hematologic malignancies among adults for which the chimeric monoclonal anti-CD20 antibody (Ab) rituximab (RTX) is used as first-line therapy. As RTX itself is not directly cytotoxic but relies on host immune effector mechanisms or chemotherapeuti...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Chengke, Deng, Zhenghao, Li, Lan, Clayton, Frederic, Chen, Alexander L., Wei, Ran, Miles, Rodney, Stephens, Deborah M., Glenn, Martha, Wang, Xiyang, Jensen, Peter E., Chen, Xinjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914323/
https://www.ncbi.nlm.nih.gov/pubmed/26859679
http://dx.doi.org/10.18632/oncotarget.7230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914323/
https://www.ncbi.nlm.nih.gov/pubmed/26859679
http://dx.doi.org/10.18632/oncotarget.7230

Ejemplares similares